Finance

Lists
CRVS:NASDAQ
Corvus Pharmaceuticals Inc
US$ ९.३८
-०.३२%
(-०.०३०) 1D
US$ ९.४०
+०.२१% (+०.०२०)
Pre-market
Closed: अक्टोबर १४, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRVS...
Open
US$ ९.३१
High
US$ ९.५०
Low
US$ ९.२१
Mkt. cap
७८.९१ करोड
Avg. vol.
११.९६ लाख
Volume
१.००
52-wk high
US$ २६.९५
52-wk low
US$ ६.३९
EPS
-US$ ०.६२
Beta
१.४४
Shares outstanding
८.४१ करोड
No. of employees
३७
Open
US$ ९.३१
High
US$ ९.५०
Low
US$ ९.२१
Mkt. cap
७८.९१ करोड
Avg. vol.
११.९६ लाख
Volume
१.००
52-wk high
US$ २६.९५
52-wk low
US$ ६.३९
EPS
-US$ ०.६२
Beta
१.४४
Shares outstanding
८.४१ करोड
No. of employees
३७
News stories
From web sources and news partners
About Corvus Pharmaceuticals Inc
CEO-
Employees३७
Founded२०१४
HeadquartersBurlingame, क्यालिफोर्निया, संयुक्त राज्य अमेरिका
Sector-
Analyst ratings
Based on 4 analysts giving stock ratings to CRVS in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for CRVS in the last 3 months.
Highest
Current US$ ९.३८
US$ ३३.०० (+२५१.८१%)
Average
US$ २९.५० (+२१४.५०%)
Lowest
US$ २७.०० (+१८७.८५%)
Analyst
Recommendation
Action
Price target
Projected
Date
Graig Suvannavejh
Mizuho Securities
Buy
Reiterated
US$ ३०.००
+२१९.८%
08/11/2026
Sean Lee CFA
H.C. Wainwright
Buy
Maintained
US$ २७.००
+१८७.८%
08/10/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
US$ ३३.००
+२५१.८%
08/07/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
US$ ३३.००
+२५१.८%
08/07/2026
Etzer Darout
Barclays
Buy
Maintained
US$ २८.००
+१९८.५%
08/07/2026
Paul Choi
Goldman Sachs
Buy
Maintained
US$ ४०.००
+३२६.४%
05/14/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
८४.५४ लाख
९९.३९ लाख
१.१२ करोड
१.६० करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
२१.१८ लाख
२२.७८ लाख
३७.०२ लाख
३३.३३ लाख
Operating expense
१.०६ करोड
१.२२ करोड
१.४९ करोड
१.९३ करोड
Total operating expenses
१.०६ करोड
१.२२ करोड
१.४९ करोड
१.९३ करोड
Operating income
-१.०६ करोड
-१.२२ करोड
-१.४९ करोड
-१.९३ करोड
Other non operating income
-
-
-
-
EBT including unusual items
-१.०२ करोड
-१.२३ करोड
-१.३७ करोड
-१.८० करोड
EBT excluding unusual items
-१.०२ करोड
-१.२३ करोड
-१.३७ करोड
-१.८० करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-१.०२ करोड
-१.२३ करोड
-१.३७ करोड
-१.८० करोड
Net profit margin
-
-
-
-
Earnings per share
-०.१२
-०.१५
-०.१५
-०.१९
Interest and investment income
७.३८ लाख
६.०३ लाख
१७.८४ लाख
२०.४७ लाख
Interest expense
-
-
-
-
Net interest expenses
७.३८ लाख
६.०३ लाख
१७.८४ लाख
२०.४७ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-१.०५ करोड
-१.२२ करोड
-१.४८ करोड
-१.९३ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू